Stephen L. Sabba - Dec 22, 2022 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
Director
Signature
/s/ Andrew Reardon, Attorney-in-Fact for Stephen L. Sabba
Stock symbol
LGND
Transactions as of
Dec 22, 2022
Transactions value $
$0
Form type
4
Date filed
12/27/2022, 05:30 PM
Previous filing
Jun 14, 2022
Next filing
May 12, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LGND Non-Qualified Stock Option (right to buy) Award $0 +6.62K $0.00 6.62K Dec 22, 2022 Common Stock 6.62K $67.03 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Grant to reporting person of stock options that will vest and become exercisable on December 22, 2023.

Remarks:

Exhibit 24 - Power of Attorney.